Drug Profile
Research programme: tuftsin based therapeutics - Endocyte
Alternative Names: Anti-inflammatory therapeutics - Endocyte; Pentapeptide tuftsin analogue - Endocyte; Tetrameric tuftsin aminopterin conjugate - Endocyte; TKPPR - EndocyteLatest Information Update: 31 Dec 2018
Price :
$50
*
At a glance
- Originator Endocyte
- Class Drug conjugates; Peptide fragments; Peptides
- Mechanism of Action Immunosuppressants; Macrophage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 21 Dec 2018 Endocyte has been acquired by Novartis
- 28 Feb 2018 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Feb 2018 No recent reports of development identified for research development in Inflammation in USA